Keywords
SHPT and THPT
quality of life
SPF-36
subtotal parathyroidectomy
integrated patient management
How to Cite
Abstract
Introduction. The problem of secondary hyperparathyroidism (SHPT) and tertiary hyperparathyroidism (THPT) has drawn the attention of numerous researchers in many countries, including those where kidney transplantation is a routine procedure. The most acute aspects include determining the most effective methods of therapeutic treatment, diagnostic and prognostic criteria, indications for surgery, its scope, and methods of avoiding relapses.
The aim. To study the quality of life of patients who underwent surgery for secondary and tertiary hyperparathyroidism on the background of chronic kidney disease.
Materials and Methods. During the study, we conducted a survey of 60 patients with secondary and tertiary hyperparathyroidism who underwent surgery between 2020 and 2023. The surveys were conducted twice: before the surgical intervention and within a period of up to 9 months after it. Among those surveyed, there were 35 (58%) women and 25 (42%) men. The average age of the respondents was 51.31±9.16 years.
Results and Discussion. Quality of life is one of the most important indicators of the effectiveness of treatment. We observed an improvement in the quality of life in all surveyed patients with Tertiary Hyperparathyroidism (THPT) after surgical treatment. From the physical component point of view, this effect is undoubtedly associated with a decrease in the level of PTH and ionized calcium in the blood. This is evidenced by the significant correlation between these indicators and the obtained values of physical functioning scales before and after the operation.
Conclusions. A significant correlation was observed between the levels of parathyroid hormone, ionized calcium, and physical functioning scales before and after surgery.
References
Pariy, V. D., Hryshchuk, S. M. (2021). Pidkhody do likuvannya khvoroby vid khvoroby nyrok V stupeni v Ukrayini. In: Farmakoekonomika v Ukrayini: stan ta perspektyvy rozvytku: materialy KHIII nauk.-prakt. INTERNET-konf. [Approaches to the treatment of kidney disease B stage in Ukraine. In: Pharmacoeconomics in Ukraine: state and prospects of development: materials of the 13th scientific-practical conference]. Kharkiv. [in Ukrainian].
Dudar I.O., Palamar B.I., Krasyuk E.K., Petrova A.S. (2015). Poshyrenistʹ KHKHN VD stadiyi u sviti ta v Ukrayini [Prevalence of CKD VD stage in the world and in Ukraine.]. Health of Ukraine, (3-4), 10-12. [in Ukrainian].
Kondratyuk V.YE., Petrova A.S. (2018). Otsinka yakosti snu ta zhyttya u patsiyentiv z khronichnoyu khvoroboyu nyrok, shcho znakhodyatʹsya na likuvanni metodom hemodializu [Assessment of the quality of sleep and life in patients with chronic kidney disease undergoing hemodialysis treatment]. Aktualʹni problemy nefrolohiyi, (24), 37-40. [in Ukrainian].
Kolesnyk, M.O. (2017). Natsionalnyi reiestr khvorykh na khronichnu khvorobu nyrok ta patsiientiv z hostrym poshkodzhenniam nyrok: 2016 rik [National Register of Patients with Chronic Kidney Disease and Patients with Acute Kidney Injury: 2016]. Kyiv. [in Ukrainian].
Kravets, O.V., Myslovskyi, I.A., & Popadynets, V.M. (2018). Khirurhichni aspekty perytonealnoho dializu: profilaktyka, diahnostyka, ta likuvannia uskladnen [Surgical aspects of peritoneal dialysis: prevention, diagnosis and treatment of complications]. Ukrainskyi medychmyi chasopys – Ukrainian Medical Herald, 3(2) (125) -V/VI, 40-43 [in Ukrainian].
Maystruk, S. B., Shaprins'kiy, V. A., Pritulyak, L. V., Pivovarova, N. I., & Palamarchuk, A. V. (2019). Otsenka rezul'tatov khirurgicheskogo lecheniya bol'nykh so vtorichnym i tretichnym iperparatireozom na fone khronicheskoy pochechnoy nedostatochnosti, prozhivayushchikh v Vinnitskoy oblasti [Evaluation of the results of surgical treatment of patients with secondary and tertiary hyperparathyroidism against the background of chronic renal failure, living in the Vinnitsa region]. Clinical endocrinology and endocrine surgery, (3), 55-60.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.